Cargando…
Tumor genome analysis includes germline genome: Are we ready for surprises?
We sought to describe the spectrum of potential and confirmed germline genomic events incidentally identified during routine medium-throughput somatic tumor DNA sequencing, and to provide a framework for pre- and post-test consent and counseling for patients and families. Targeted tumor-only next-ge...
Autores principales: | Catenacci, Daniel VT, Amico, Andrea L, Nielsen, Sarah M, Geynisman, Daniel M, Rambo, Brittany, Carey, George B, Gulden, Cassandra, Fackenthal, Jim, Marsh, Robert D, Kindler, Hedy L, Olopade, Olufunmilayo I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303936/ https://www.ncbi.nlm.nih.gov/pubmed/25123297 http://dx.doi.org/10.1002/ijc.29128 |
Ejemplares similares
-
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
por: Geynisman, Daniel M, et al.
Publicado: (2013) -
Racial differences in a high-risk colorectal cancer referral population: a single-center experience
por: Gulden, Cassandra, et al.
Publicado: (2011) -
Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
por: Catenacci, Daniel V.T.
Publicado: (2014) -
Progress, Challenges, and Surprises in Annotating the Human Genome
por: Zerbino, Daniel R., et al.
Publicado: (2020) -
Addressing health disparities in cancer with genomics
por: Balogun, Onyinye D., et al.
Publicado: (2021)